In this cohort study, we found that men with prostate cancer residing in US counties with a higher prevalence of PSA screening experienced lower odds of advanced stage disease and lower rates of all-cause and prostate cancer–specific mortality. This evidence concerns the gene KLK3 and prostate carcinoma.